THE FUTURE OF SICKLE CELL DISEASE TREATMENT AND MANAGEMENT
WE UNDERSTAND YOU
NeuTigers is currently conducting clinical studies aimed at preventing the painful crisis associated with sickle cell diseases. The ultimate goal is to use artificial Intelligence solutions to detect the first physiologic signals of vaso-occlusive crisis of sickle cell disease, allowing for earlier interventions and improved patient outcomes.
- Maximize quality of life and well-being
- Increase social participation and vocational integration
- Expedite clinical studies
- Harness the power of omics data
- Reduce the inherent risk of clinical trials
- Maximize small sample of data with our Synthetic Data Libraries
- Emphasize preventive care
Reduce cost of care
- Improve patient outcomes
- Increase research for comprehensive and coordinated care
- Offer personalized care
Intervene in high-risk patients before sickle cell crisis
- Improve follow up
- Reduce risk and increase profit margins
- Gain a better understanding of your community
- Proactively alert physicians of at-risk patients
- Support a healthier lifestyle
- Collect precise information to empower your members
- Precise real-time diagnostics and monitoring
Sickle Cell Disease (SCD) is a genetic blood disorder that affects over 20 million people globally and approximately 100,000 people in the United States.
The hallmarks of SCD are acute and chronic vaso-occlusive pain crises (VOC), stroke, chronic kidney disease (CKD), end-stage renal disease (ESRD), pulmonary hypertension (PH), and chronic hemolytic anemia.
To date, the only cure for SCD is a costly and invasive procedure called hematopoietic stem cell transplantation (HSCT).
Barriers that preclude its widespread use include:
Difficulties in finding a matched donor High mortality risk.
High risk of acute complications in the immediate post-transplant period.
Living with SDC means endless doctor visits, hospital stays, and blood transfusions. When an acute sickle crisis occurs, a patient can be hospitalized for several days, sometimes requiring an analgesic coma.
We pride ourselves on having a research and development team led by people with Sickle Cell Disease.
SickleDeep is a product of the StarDeep suite. This includes a library of health conditions that detects and monitors disease via a smartwatch and the most advanced AI model.
- Vaso-occlusive crisis detection & diagnosis tool
- Breakthrough AI based on predictive models
- Commercial wearable sensors that collect digital biomarkers
- Clinically validated via clinical partners
CareDeep is a community-focused care coordination platform. It provides better engagement improved Remote Monitoring and reduce the effects of chronic conditions.
With CareDeep patients learn to preempt crises and their painful effects.
We combined the population health insights from ServiceDeep, our health analytics solution with the real-time wearable analytics of SickleDeep to produce:
- A provider dashboard with actionable patient information displayed on a user-friendly interface
- A healthcare Coordination platform with remote communication & care management
- A patient chatbot, decision aid, and health recommendation system for symptoms prevention, self-care management, and community engagement to support day-to-day tasks and patient-important information needs.
NeuTigers is currently conducting studies of Sickle Cell Disease patients’ remote detection and prevention health platform to identify the digital signatures of impending chronic vaso-occlusive crises (VOC).
This will allow for early intervention while improving patients’ health outcomes and overall quality of life. The study is taking place at Assistance Publique-Hôpitaux de Paris (AP-HP) under the supervision of Professor Frédéric Galacteros.
NeuTigers Clinical Study with Prof. Galacteros
Four minutes excerpt of our conversation with Professor Frédéric Galactéros, a specialist in sickle cell disease, about a NeuTigers clinical study on the use of wearable devices and artificial intelligence (AI) to prevent vaso-occlusive crises.
Watch the full interview here.